Content of receptor for advanced glycation endproduct (RAGE) and matrix metalloproteinase of 2 type in blood serum of bone tumor patients
Aim of the study : comparative analysis of receptor for advanced glycation end product (RAGE) and matrix metalloproteinase 2 (MMP-2) content in blood serum of bone tumor patients and healthy persons. Materials and methods : 115 primary bone tumor patients (64 male and 51 female) aged 16-75 years were enclosed in the study including 63 patients with malignant (osteosarcoma - 18, chondrosarcoma - 38, Ewing sarcoma - 4, undifferentiated pleomorphic sarcoma - 1, chordoma - 2), 26 - with borderline (all - giant-cell bone tumors), and 26 with benign lesions. Control group comprised 40 age-matched practically healthy persons (18 male and 22 female). RAGE and ММР-2 levels were measured in blood serum before the onset of treatment with corresponding standard ELISA kits (“R&D”, USA). Results : RAGE levels in the serum of patients with bone sarcomas and borderline tumors were significantly lower than in control group, and were not gender-dependent in both control and bone tumor groups. No correlation was revealed between RAGE levels and age of healthy persons, while a negative association between RAGE and bone tumor patients' age was found. Serum RAGE was higher in osteosarcoma than in chondrosarcoma patients, and in patients with chondrosarcoma it was significantly lower than in those with benign bone tumors. RAGE concentration in blood serum was significantly higher in patients with poorly differentiated than in those with highly differentiated bone tumors, and in patients with tumors affecting tubular as compared to flat bones. Serum MMP-2 levels were significantly higher in control group than in patients with malignant and borderline bone tumors. The lowest ММР-2 levels were found in osteosarcoma and chondrosarcoma patients. MMP-2 levels in blood serum were not associated with bone sarcomas' differentiation grade. No correlation between RAGE and MMP-2 serum levels were found either in the total patients' group, or in individual tumor type groups. Conclusion : RAGE and ММР-2 serum levels are decreased in bone tumor patients as compared to practically healthy control and depend on tumor histological type and differentiation grade, as well as on the type of affected bone. These differences may reflect the pathogenetic peculiarities of various bone tissue neoplasms.